# US 12,006,283 B2 · HIF-1α inhibitor, preparation method therefor, and pharmaceutical composition for preventing or treating angiogenesis-associated eye disease, containing same as active ingredient

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,006,283 B2
- Document ID: US12006283B2
- Status: Granted
- Kind: B2
- Application number: 17/057,297
- Filed: 2019-08-12
- Published: 2021-06-24
- Granted: 2024-06-11
- Earliest claimed: 2018-08-31
- Assignees: Seoul National University R&Db Foundation
- Applicants: Seoul National University R&Db Foundation
- Inventors: Youngger Suh; Seungbeom Lee; Jeonghun Kim
- Web page: https://patentgrep.com/patent/US12006283B2

## CPC

- C07C 49/84: containing ether groups, [IMAGE cpc-sch-C07C-0958.gif] groups,[IMAGE cpc-sch-C07C-0959.gif] groups, or[IMAGE cpc-sch-C07C-0960.gif] groups
- A61K 31/12: Ketones
- A61P 27/02: Ophthalmic agents
- C07C 225/22: having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C 255/58: containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
- C07C 255/59: the carbon skeleton being further substituted by singly-bound oxygen atoms
- C07D 207/06: with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D 207/08: with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D 211/08: with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D 211/22: by oxygen atoms
- C07D 265/30: not condensed with other rings
- C07C 2601/14: The ring being saturated
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Disclosed are a novel hypoxia-inducible factor 1α (HIF-1α) inhibitor, a method of preparing the same, and a pharmaceutical composition for preventing or treating an angiogenesis-related eye disease containing the same as an active ingredient. The compound of Example provided according to an embodiment of the present invention is capable of effectively inhibiting HIF-1α and is thus useful as a pharmaceutical composition for preventing or treating an angiogenesis-related eye disease.

## Claims

### Claim 1

A compound represented by the following Formula (1), or a solvate, hydrate, optical isomer or pharmaceutically acceptable salt thereof:
A1 and A2 are methoxy or A1 is H and A2 is F;
B1 is —H, or C1-10 straight- or branched-chain alkoxy; and
R1 is C3-10 cycloalkyloxy, heterocycloalkyl of a 5- to 10-membered ring containing at least one heteroatom selected from the group consisting of N, O and S, or benzylamino unsubstituted or substituted with —CN.

### Claim 2 (depends on 1)

The compound or a solvate, hydrate, optical isomer, or pharmaceutically acceptable salt thereof according to claim 1, wherein B1 is C1-10 straight- or branched-chain alkoxy, and R1 is heterocycloalkyl of a 5-membered ring containing N.

### Claim 3 (depends on 1)

The compound or a solvate, hydrate, optical isomer, or pharmaceutically acceptable salt thereof according to claim 1, wherein the compound of Formula 1 is selected from the group consisting of the following compounds:

### Claim 4 (depends on 1)

A method of treating or preventing an angiogenesis-related eye disease in a subject, the method comprising administering a pharmaceutically effective amount of the compound according to claim 1 to the subject.

### Claim 5 (depends on 4)

The method according to claim 4, wherein the angiogenesis-related eye disease is age-related macular degeneration, diabetic retinopathy, retinopathy of prematurity, or neovascular glaucoma.